
![]() |
|||||||||||||
WJPR Citation Report
|
| All | Since 2021 | |
| Citation | 9186 | 4781 |
| h-index | 32 | 25 |
| i10-index | 256 | 108 |
FROM DOSSIER TO APPROVAL: A COMPARATIVE REVIEW OF SUBMISSION FRAMEWORKS ACROSS THE FDA, HEALTH CANADA, AND EMA
J. Swapna, M. Swetha, B. Chandra Shekhar Reddy*
Abstract Regulatory submissions serve as the formal mechanism by which sponsors demonstrate that a medicinal product meets jurisdiction-specific standards for quality, safety, and efficacy. While the United States Food and Drug Administration (US FDA), Health Canada, and the European Medicines Agency (EMA), along with national competent authorities, extensively rely on International Council for Harmonization (ICH) principles and the Common Technical Document (CTD), their legal frameworks, application routes, review management, expedited pathways, and post-authorization obligations differ. This review systematically compares these three regulatory systems for human medicinal products, focusing on investigational-stage authorization, marketing applications, dossier architecture, electronic submission, review timelines, lifecycle management, and pharmacovigilance. The FDA operates through a federal agency model utilizing IND, NDA, ANDA, and BLA pathways; Health Canada implements the Food and Drugs Act and Food and Drug Regulations via clinical trial applications and NDS/ANDS families; and the EU integrates EMA scientific coordination with European Commission decisions for centralized products and national authority procedures for other products. Although a shared CTD core enables dossier reuse, regional Module 1, forms, labeling, administrative data, and procedural expectations remain distinct. Illustrative timelines clarify that published review targets should not be interpreted as total development-to-market durations, as clock stops, screening, sponsor response periods, and post-opinion decision steps vary. Practical examples demonstrate how a single global dossier can be adapted for three regions without presuming that approval in one jurisdiction automatically confers access to another market. The review concludes that early regulatory strategy, robust data, lifecycle-ready eCTD publishing, and region-specific planning are critical for efficient global development. Keywords: regulatory submissions; US FDA; Health Canada; European Medicines Agency; CTD; eCTD; NDA; NDS; marketing authorization; pharmacovigilance. [Full Text Article] [Download Certificate] |
